Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
This study is a randomized trial that will compare progression free survival between Regorafenib + FOLFORI chemotherapy versus placebo + FOLFORI in patients with metastatic colorectal cancer and KRAS or BRAF mutant disease previously treated with a FOLFOX regimen.
Who may be Eligible  
Second-Line therapy in patients with K-RAS or BRAF mutant with metastatic colorectal cancer.
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Email:  Delois.DeShazo@carolinashealthcare.org
Address:1100 S. Tryon Street Suite 220 Charlotte, NC 28203